• Vaccine Name: rORFV-PRV-gC/gD
• Target Pathogen: Pseudorabies virus
• Target Disease: Aujeszky's disease
• Vaccine Ontology ID: VO_0004770
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Vector:
  • Vector name:
  • VO vector ID: VO_0001108
  • Description: (Fischer et al., 2003)
• Preparation: Based on the attenuated ORFV strain D1701-V, recombinants were produced that express the glycoproteins gC (D1701-VrVgC) or gD (D1701-VrVgD) of the alphaherpesvirus of swine, pseudorabies virus (PRV) (Fischer et al., 2003).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: Mice were injected intramuscularly (i.m.) with 107 TCID50s of the ORFV recombinants expressing the PRV glycoproteins in a total volume of 0.2 ml (0.1 ml for each hind leg). Immunization was repeated at 2-week intervals (Fischer et al., 2003).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Mice were challenge infected intraperitoneally (i.p.) with 10^2 PFU of the highly virulent PRV strain NIA-3, and the C57BL/6 and 129/Sv/Ev mice were infected with 10^3 PFU
• Efficacy: Single or combined immunization with the ORFV recombinants protected different mouse strains of a host species nonpermissive for ORFV against a fulminant, lethal PRV challenge infection equal to immunization with PRV live vaccine. Most notably, even a single immunization with D1701-VrVgC was protective, whereas two applications of D1701-VrVgD were required for immune protection (Fischer et al., 2003).